Results 121 to 130 of about 3,353 (184)

<i>In vitro</i> activity of aztreonam-nacubactam and cefepime-nacubactam against a global collection of clinically important Gram-negative Bacilli collected in 2021-2023. [PDF]

JAC Antimicrob Resist
Karlowsky JA, Estabrook M, Suzuki E, Shimizu A, Okade H.   +4 more
europepmc   +1 more source

Antimicrobial Susceptibility of <i>Pseudomonas aeruginosa</i> from Elderly Patients in Intensive Care Units of United States Medical Centers (2021-2025). [PDF]

Antibiotics (Basel)
Sader HS, Mendes RE, Doyle TB, Winkler ML, Castanheira M.   +4 more
europepmc   +1 more source

<i>In vitro</i> activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan. [PDF]

JAC Antimicrob Resist
Yanagihara K, Tateda K, Doi Y, Takahashi S, Ohge H, Itahashi K, Okade H, Mikamo H.   +7 more
europepmc   +1 more source

Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016-2024). [PDF]

J Antimicrob Chemother
Sader HS, Papp-Wallace KM, Kimbrough JH, Debabov D, Mendes RE, Castanheira M.   +5 more
europepmc   +1 more source

When might we consider using the newer β-lactam agents as empirical therapy against presumed carbapenem-resistant gram-negative infections? [PDF]

JAC Antimicrob Resist
Assimakopoulos SF, Ioannou S, Rodriguez-Bano J, Marangos M, Daikos GL.   +4 more
europepmc   +1 more source

Carbapenem-resistant Gram-negative pathogens: molecular epidemiology, diagnostic advances, and emerging therapeutic strategies. [PDF]

Front Microbiol
Khan M, Patil P, Rathored J.
europepmc   +1 more source

Case Commentary: When one target is not enough-PBP3 insertions and target redundancy in <i>Escherichia coli</i>. [PDF]

Antimicrob Agents Chemother
Stellfox ME, Doi Y.
europepmc   +1 more source

Emergence of KPC-producing <i>Pseudomonas aeruginosa</i> in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam. [PDF]

Antimicrob Agents Chemother
Pérez-Rodríguez G, Aja-Macaya P, González-Pinto L, Taltavull B, Tarriño-León M, Gallardo-García MdM, Blanco-Martín T, Rodríguez-Pallares S, Sánchez-Peña L, Moscoso M, Beceiro A, Oliver A, Bou G, Arca-Suárez J.   +13 more
europepmc   +1 more source

Avibactam-based combinations for the treatment of multidrug resistant Gram-negative bacilli infections. [PDF]

Infez Med
Tiseo G, Russo A, Bartoletti M, Tumbarello M, Falcone M.   +4 more
europepmc   +1 more source

In Vitro Activity of Cefiderocol, Eravacycline, and Imipenem-Relebactam Against Multidrug-Resistant <i>Acinetobacter baumannii</i> Clinical Isolates. [PDF]

Antibiotics (Basel)
Bölükbaşı Y, Öngen B.
europepmc   +1 more source